Crossmark Global Holdings Inc. Acquires 18,670 Shares of Haleon plc (NYSE:HLN)

Crossmark Global Holdings Inc. boosted its holdings in Haleon plc (NYSE:HLN) by 3.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 499,430 shares of the company’s stock after purchasing an additional 18,670 shares during the period. Crossmark Global Holdings Inc.’s holdings in Haleon were worth $4,764,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Haleon by 5.8% in the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after acquiring an additional 5,768,117 shares in the last quarter. Sculptor Capital LP boosted its position in Haleon by 67.8% during the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock valued at $73,407,000 after purchasing an additional 3,592,000 shares during the last quarter. Clearbridge Investments LLC grew its stake in Haleon by 8.6% in the second quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock valued at $344,888,000 after purchasing an additional 3,307,009 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Haleon by 49.9% during the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after purchasing an additional 3,046,841 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after purchasing an additional 1,026,939 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Finally, UBS Group raised shares of Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Haleon has a consensus rating of “Moderate Buy” and a consensus target price of $10.95.

Haleon Stock Down 0.2 %

HLN stock opened at $9.23 on Thursday. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80. The business’s 50 day simple moving average is $9.54 and its 200 day simple moving average is $9.72. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $41.76 billion, a PE ratio of 27.13, a PEG ratio of 2.59 and a beta of 0.29.

Haleon (NYSE:HLN) last released its quarterly earnings data on Thursday, October 31st. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.11 by $0.03. The firm had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.74 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. During the same period in the previous year, the company earned $0.10 earnings per share. As a group, research analysts anticipate that Haleon plc will post 0.44 EPS for the current year.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.